Thursday 9th February 2017Dissolution testing: current and future considerationsRoyal Society of Chemistry, London
Dissolution and disintegration tests for solid oral dosage forms provide insight into the rate of release of the drug into the body. Dissolution has been viewed solely as a quality control tool, but more recently this view has started to change and now there is clear expectation that dissolution must have clinical relevance.
However, the challenge remains: how can a single test be sensitive enough to predict changes that may be of clinical relevance, whilst being robust enough to satisfy the needs of a quality control environment?
This symposium will explore the current state of these techniques from a regulatory, pharmacopoeia, academic and industry perspective, and how emerging bio-relevant dissolution tools can improve our prediction of oral drug behaviour.
This symposium should be attractive to scientists working in research & development, quality control, regulatory, pharmacopoeias and academia. In addition senior managers will benefit from attending. This symposium is organised in association with the OrBiTo consortium.
Dr Karl Box - Sirius Analytical
Dr Karin Bracht - MHRA
Dr James Butler - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr Edmund Kostewicz - Frankfurt University
Dr James Mann - AstraZeneca
Steve Young - MHRADETAILS